SCHEMBL3013465

SCHEMBL3013465

Cc1cccc(-c2csc(N3CCC(S(=O)(=O)c4cccc(F)c4)CC3)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
MAPT P10636 3/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 10/20 0.46
FAAH O00519 1/20 0.45
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010240 0.93 RAB9A (0.47) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3017062 0.91 MAPT (0.56) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3021646 0.91 SMN1; SMN2 (0.53) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3006285 0.90 SMN1; SMN2 (0.53) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3022723 0.90 RAB9A (0.47) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3016646 0.89 RAB9A (0.48) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3010126 0.89 SMN1; SMN2 (0.56) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3016195 0.89 RAB9A (0.48) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3014861 0.88 SMN1; SMN2 (0.47) RAB9ANPC1MAPTUSP2RECQL
SCHEMBL3010156 0.88 SMN1; SMN2 (0.52) RAB9ANPC1MAPTUSP2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885NPC1 15/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.